Bear Stearns keeps MedImmune at outperform

MedImmune Inc. was maintained by Bear Stearns analyst Mark Schoenebaum at outperform following a meeting with MedImmune management. The Synagis franchise is unlikely to crumble this season, according to the analyst. The company is ahead of last season in terms of Synagis distributor contracts, sales training and patient tracking. Shares of the Gaithersburg, Md.-based biotechnology company were up $1.40, or 5.37%, at $27.47, on volume of 4,706,072 shares versus the three-month running average of 3,060,620 shares. (Nasdaq: MEDI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.